A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies showed ...
Average premiums and benefits for Medicare's prescription drug program and private Medicare plans are projected to remain ...
British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
The U. S. Food and Drug Administration (FDA) has signed off on Cobenfy, the first revolutionary treatment for schizophrenia ...
The U.S. Food and Drug Administration (FDA ... Chris Boerner, board chair and chief executive officer at Bristol Myers Squibb ...
U.S. equities were mixed at midday as the Federal Reserve's favored measure of inflation was lower than anticipated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback